Mireia Mallandrich

Dr. Mireia Mallandrich

Farmàcia i Tecnologia Farmacèutica, i Fisiquímica, Universitat de Barcelona, Barcelona, Catalonia, Spain
orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2012 in Nanomedicine: Nanotechnology, Biology and Medicine
Verified
Journal Article
Closed access
JAJoana Araújo
Joana Araújo
MGMaria L. Garcia
Maria L. Garcia
Mireia MallandrichMireia Mallandrich
Mireia Mallandrich
Eliana B. SoutoEliana B. Souto
Eliana B. Souto
ANA CRISTINA CALPENAANA CRISTINA CALPENA
ANA CRISTINA CALPENA

14 July 2021 in Polymers
Verified
Journal Article
Open access
PDF file
MAMuhammad Akhlaq
Muhammad Akhlaq
AAAbul Azad
Abul Azad
AAAbul Azad
Abul Azad
Asif NawazAsif Nawaz
Asif Nawaz
MSMuhammad Safdar
Muhammad Safdar
HNH. P. Nagaswarupa
H. P. Nagaswarupa
The aim was to formulate and evaluate Gel/PVA hydrogels as a pH-sensitive matrix to deliver methotrexate (MTX) to colon. The primed Gel/PVA hydrogels were subjected to evaluation for swelling behavior, diffusion coefficient, sol-gel characteristic and porosity using an acidic (pH 1.2) and phosphate buffer (PBS) (pH 6.8 & pH 7.4) media. Fourier transform infrared spectroscopy (FTIR) and thermal gravimetric analysis (TGA) were performed to evaluate the chemical compatibility of the Gel/PVA hydrogel. The shape alteration and release of Gel/PVA hydrogel was conducted at pH 1.2, pH 6.8 and pH 7.4. The drug release kinetic mechanism was determined using various kinetic equations. The physicochemical evaluation tests and drug release profile results were found to be significant (p < 0.01). However, it was dependent on the polymers’ concentration, the pH of the release media and the amount of the cross-linking agent. Hydrogels containing the maximum amount of gel showed a dynamic equilibrium of 10.09 ± 0.18 and drug release of 93.75 ± 0.13% at pH 1.2. The kinetic models showed the release of MTX from the Gel/PVA hydrogel was non-Fickian. The results confirmed that the newly formed Gel/PVA hydrogels are potential drug delivery systems for a controlled delivery of MTX to the colon.

29 November 2019 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
SBSánchez Milán Aroha Belén
Sánchez Milán Aroha Belén
ANA CRISTINA CALPENAANA CRISTINA CALPENA
ANA CRISTINA CALPENA
Mireia MallandrichMireia Mallandrich
Mireia Mallandrich
BCBeatriz Clares-Naveros
Beatriz Clares-Naveros
The absorption study of drugs through different biological membranes constitutes an essential step in the development of new pharmaceutical dosage forms. Concerning orally administered forms, methods based on monolayer cell culture of Caco-2 (Caucasian colon adenocarcinoma) have been developed to emulate intestinal mucosa in permeability studies. Although it is widely accepted, it has disadvantages, such as high costs or high technical complexity, and limitations related to the simplified structure of the monolayer or the class of molecules that can be permeated according to the transport mechanisms. The aim of this work was to develop a new ex vivo methodology which allows the evaluation of the intestinal apparent permeability coefficient (Papp) while using fewer resources and to assess the correlation with Caco-2. To this end, pig (Sus scrofa) duodenum segments were mounted in Franz diffusion cells and used to permeate four different drugs: ketorolac tromethamine (Kt), melatonin (Mel), hydrochlorothiazide (Htz), and furosemide (Fur). No statistically significant differences (p > 0.05) were observed corelating Papp values from Franz diffusion cells and Caco-2 cell experiments for Kt, Htz, and Fur. However, there were statistically significant differences (p < 0.05) correlating Papp values and Mel. The difference is explained by the role of Mel in the duodenal epithelial paracellular permeability reduction. Ex vivo permeation may be an equivalent method to Caco-2 for drugs that do not produce intestinal membrane phenomena that could affect absorption.

29 September 2021 in Polymers
Verified
Journal Article
Open access
PDF file
AAAbul Azad
Abul Azad
AAAbul Azad
Abul Azad
SFShivkanya Fuloria
Shivkanya Fuloria
Asif NawazAsif Nawaz
Asif Nawaz
Vetriselvan SubramaniyanVetriselvan Subramaniyan
Vetriselvan Subramaniyan
NFNeeraj Fuloria
Neeraj Fuloria
The purpose of the present study was to develop emulsions encapsulated by chitosan on the outer surface of a nano droplet containing 5-fluorouracil (5-FU) as a model drug. The emulsions were characterized in terms of size, pH and viscosity and were evaluated for their physicochemical properties such as drug release and skin permeation in vitro. The emulsions containing tween 80 (T80), sodium lauryl sulfate, span 20, and a combination of polyethylene glycol (PEG) and T20 exhibited a release of 88%, 86%, 90% and 92%, respectively. Chitosan-modified emulsions considerably controlled the release of 5-FU compared to a 5-FU solution (p < 0.05). All the formulations enabled transportation of 5-FU through a rat’s skin. The combination (T80, PEG) formulation showed a good penetration profile. Different surfactants showed variable degrees of skin drug retention. The ATR-FTIR spectrograms revealed that the emulsions mainly affected the fluidization of lipids and proteins of the stratum corneum (SC) that lead to enhanced drug permeation and retention across the skin. The present study concludes that the emulsions containing a combination of surfactants (Tween) and a co-surfactant (PEG) exhibited the best penetration profile, prevented the premature release of drugs from the nano droplet, enhanced the permeation and the retention of the drug across the skin and had great potential for transdermal drug delivery. Therefore, chitosan-coated 5-FU emulsions represent an excellent possibility to deliver a model drug as a transdermal delivery system.

24 May 2017 in Pharmaceutical Research
Verified
Journal Article
Closed access
PDF file
Mireia MallandrichMireia Mallandrich
Mireia Mallandrich
Francisco Fernandez-CamposFrancisco Fernandez-Campos
Francisco Fernandez-Campos
BCBeatriz Clares-Naveros
Beatriz Clares-Naveros
LHLyda Halbaut-Bellowa
Lyda Halbaut-Bellowa
CACristina Alonso
Cristina Alonso
ANA CRISTINA CALPENAANA CRISTINA CALPENA
ANA CRISTINA CALPENA

23 January 2021 in Gels
Verified
Journal Article
Open access
PDF file
SMSalima El El Moussaoui El Masnaoui
Salima El El Moussaoui El Masnaoui
Francisco Fernandez-CamposFrancisco Fernandez-Campos
Francisco Fernandez-Campos
CACristina Alonso
Cristina Alonso
David LimónDavid Limón
David Limón
LHLyda Halbaut-Bellowa
Lyda Halbaut-Bellowa
Mireia MallandrichMireia Mallandrich
Mireia Mallandrich
Condyloma acuminata is an infectious disease caused by the human papilloma virus (HPV) and one of the most common sexually transmitted infections. It is manifested as warts that frequently cause pain, pruritus, burning, and occasional bleeding. Treatment (physical, chemical, or surgical) can result in erosion, scars, or ulcers, implying inflammatory processes causing pain. In this work, a biocompatible topical hydrogel containing 2% ketorolac tromethamine was developed to manage the painful inflammatory processes occurring upon the removal of anogenital condylomas. The hydrogel was physically, mechanically, and morphologically characterized: it showed adequate characteristics for a topical formulation. Up to 73% of ketorolac in the gel can be released following a one-phase exponential model. Upon application on human skin and vaginal mucosa, ketorolac can permeate through both of these and it can be retained within both tissues, particularly on vaginal mucosa. Another advantage is that no systemic side effects should be expected after application of the gel. The hydrogel showed itself to be well tolerated in vivo when applied on humans, and it did not cause any visible irritation. Finally, ketorolac hydrogel showed 53% anti-inflammatory activity, suggesting that it is a stable and suitable formulation for the treatment of inflammatory processes, such as those occurring upon chemical or surgical removal of anogenital warts.